Ad­comm votes yes on Leqem­bi full OK; Mer­ck brings first IRA law­suit; Spe­cial: LGBTQ+ lead­ers; Best-pay­ing bio­phar­ma jobs; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Amid this busy week with AS­CO and BIO, you may have no­ticed a change in how our pay­wall op­er­ates. The gist of it: From now on, non-pay­ing ba­sic sub­scribers will get a lim­it­ed amount of free ar­ti­cles each month, af­ter which we’ll ask you to be­come a pre­mi­um sub­scriber to ac­cess our sto­ries. For pre­mi­um sub­scribers, noth­ing will change. Your sup­port has been cru­cial in grow­ing our news­room and we look for­ward to bring­ing more time­ly, unique and in-depth cov­er­age.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER